BIOMARIN PHARMACEUTICAL INC - Common Stock (BMRN)

CUSIP: 09061G101

Q3 2017 13F Holders as of 30 Sep 2017

Holder snapshot 7 signals
Share change
+3,453,691
Put/Call ratio
79%
SEC-reported price per share
$93.07
Indexed holders
407
Value change
+$327,519,029
Number of buys
188
Open additional details 1 more signal available
Number of sells
197
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
193,733,090

Security key

09061G101

Report period

Q3 2017

Indexed institutions

407

Top holders

10

Ownership snapshot

Top reported holders of BMRN - BIOMARIN PHARMACEUTICAL INC - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Capital Research Global I...
Disclosed value leader
Capital Research Global I...
Comparable rows
0/15
Latest evidence
30 Jun 2017
13F Highest disclosed value: $1,716,380,000 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Capital Research Global Investors has the largest disclosed position value at $1.72B.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Capital Research Global Investors's linked filing trail.
Disclosed position value Top 5
Capital Research Global Investors $1.72B
VANGUARD GROUP INC $1.3B
JENNISON ASSOCIATES LLC $1.2B
BlackRock Finance, Inc. $1.04B
PRIMECAP MANAGEMENT CO/CA/ $845.56M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Capital Research Global Investors
13F
Company
13F
—
denominator unverified
$1,716,380,000
18,898,699 shares
— 30 Jun 2017
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$1,302,816,000
14,345,027 shares
— 30 Jun 2017
JENNISON ASSOCIATES LLC
13F
Company
13F
—
denominator unverified
$1,202,709,000
13,242,773 shares
— 30 Jun 2017
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$1,035,435,000
11,400,960 shares
— 30 Jun 2017
PRIMECAP MANAGEMENT CO/CA/
13F
Company
13F
—
denominator unverified
$845,555,000
9,310,224 shares
— 30 Jun 2017
FMR LLC
13F
Company
13F
—
denominator unverified
$844,219,000
9,295,522 shares
— 30 Jun 2017
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2017

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
407
Shares
174,774,741
Indexed holders
407
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q3 2017 vs Q2 2017 Across Filers

Q2 2017 indexed holders
423
Q3 2017 indexed holders
407
Indexed holder difference
-16
Investor Q2 2017 Shares Q3 2017 Shares Share Diff Share Chg % Q2 2017 value Q3 2017 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .